+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib



The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib



Hepato-Gastroenterology 61(131): 802-808



Sorafenib has been proved to prolong survival of patients with advanced hepatocellular carcinoma (HCC), but with moderate efficacy. The present study aimed to evaluate the prognostic factors for overall survival (OS) in Chinese patients with advanced HCC treated with sorafenib who had been refractory to transarterial chemoembolization (TACE) and identify the impact of combined TACE on OS. 29 cases with advanced HCC treated with sorafenib between Feb 2009 and Sep 2012 who had been treated with TACE and finally failed to respond to TACE were included in the analysis. The survival was analysed by Kaplan-Meier Method. The clinical parameters were analysed by univariate and multivariate analysis to determine the prognostic factors of OS. Median OS of the whole cohort was 11.867 months. Combined TACE and ALB > 39.4 g/L were the independent prognostic factors associated with improved OS while Barcelona Clinic Liver Cancer (BCLC) stage C was associated with reduced OS. The overall incidence of sorafenib-related adverse effects was 82.8% and most were mild. Albumin and combined TACE is associated with improved OS in patients with advanced HCC treated with sorafenib who had been refractory to TACE. While, BCLC stage C is an independent negative prognostic factor for the OS.

(PDF emailed within 1 workday: $29.90)

Accession: 059011519

Download citation: RISBibTeXText

PMID: 26176077


Related references

Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. Plos One 9(5): E96620, 2015

Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study. Plos One 10(2): E0117168, 2016

Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review. Chinese Journal of Cancer 33(5): 259-264, 2015

Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib. World Journal of Gastroenterology 24(4): 484-493, 2018

Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib. Clinical and Translational Oncology 16(11): 1012-1017, 2015

Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology 269(2): 603-611, 2014

Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. Annals of Oncology 24(7): 1786-1792, 2013

Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma. Oncology Letters 8(5): 2263-2266, 2014

Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 32(9): 703-705, 2011

The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma. Bmc Cancer 17(1): 645, 2018

Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma. Oncotarget 7(45): 74303-74313, 2016

Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombus: A prospective control study. Journal of Vascular and Interventional Radiology 24(4): S65-S66, 2013

Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: a phase III STAH trial. Journal of Hepatology 2018, 2018

Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. Tumour Biology 36(1): 183-191, 2015

A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization. Bmc Cancer 18(1): 216, 2018